Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution

Irene Casanova‐Salas(Vall d'Hebron Hospital Universitari), Daniel Aguilar(Vall d'Hebron Hospital Universitari), Sarai Córdoba-Terreros(Vall d'Hebron Hospital Universitari), Laura Agúndez(Vall d'Hebron Hospital Universitari), Julian Brandariz(Vall d'Hebron Hospital Universitari), Nicolás Herranz(Vall d'Hebron Institut de Recerca), Alba Mas(Vall d'Hebron Hospital Universitari), Macarena González(Hebron University), Rafael Morales‐Barrera(Hebron University), Alexandre Sierra(Hebron University), Mario Soriano‐Navarro(Centro de Investigacion Principe Felipe), Pablo Cresta(Vall d'Hebron Hospital Universitari), Gisela Mir Arnau(Vall d'Hebron Hospital Universitari), S. Simonetti(Vall d'Hebron Hospital Universitari), Gonçalo Rodrigues(Vall d'Hebron Hospital Universitari), Sara Arce‐Gallego(Vall d'Hebron Institut de Recerca), Luisa Delgado-Serrano(Vall d'Hebron Hospital Universitari), Irene Agustí(Vall d'Hebron Hospital Universitari), Elena Castellano‐Sanz(Spanish National Cancer Research Centre), Richard Mast(Vall d'Hebron Hospital Universitari), Matías de Albert(Vall d'Hebron Hospital Universitari), A. Celma(Hebron University), Anna Santamaría(Hebron University), Lucila González(Vall d'Hebron Hospital Universitari), Natália Castro(Vall d'Hebron Hospital Universitari), Maria del Mar Suanes(Hebron University), Javier Hernández‐Losa(Hebron University), Lara Nonell(Vall d'Hebron Hospital Universitari), Héctor Peinado(Spanish National Cancer Research Centre), Joan Carles(Hebron University), Joaquı́n Mateo(Hebron University)
Cancer Cell
July 1, 2024
Cited by 66Open Access
Full Text

Abstract

Extracellular vesicles (EVs) secreted by tumors are abundant in plasma, but their potential for interrogating the molecular features of tumors through multi-omic profiling remains widely unexplored. Genomic and transcriptomic profiling of circulating EV-DNA and EV-RNA isolated from in vitro and in vivo models of metastatic prostate cancer (mPC) reveal a high contribution of tumor material to EV-loaded DNA/RNA, validating the findings in two cohorts of longitudinal plasma samples collected from patients during androgen receptor signaling inhibitor (ARSI) or taxane-based therapy. EV-DNA genomic features recapitulate matched-patient biopsies and circulating tumor DNA (ctDNA) and associate with clinical progression. We develop a novel approach to enable transcriptomic profiling of EV-RNA (RExCuE). We report how the transcriptome of circulating EVs is enriched for tumor-associated transcripts, captures certain patient and tumor features, and reflects on-therapy tumor adaptation changes. Altogether, we show that EV profiling enables longitudinal transcriptomic and genomic profiling of mPC in liquid biopsy.


Related Papers